Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Helene Prunier"'
Autor:
A Muraro, Helene Prunier, Dave Singh, Leonardo M. Fabbri, Alberto Papi, Stefano Vezzoli, Mario Scuri, Alessandro Guasconi, Stefano Petruzzelli
Publikováno v:
60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V..
Autor:
Alberto Papi, Helene Prunier, Dave Singh, A Muraro, Leonardo M. Fabbri, Stefano Petruzzelli, Stefano Vezzoli, Alessandro Guasconi, Mario Scuri
Publikováno v:
60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V..
Autor:
Alessandro Guasconi, Ilaria Valente, Helene Prunier, George Georges, Dave Singh, Alberto Papi, Leonardo M. Fabbri
Publikováno v:
60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V..
Autor:
Helene Prunier, Leonardo M. Fabbri, Dave Singh, Alessandro Guasconi, Alberto Papi, Stefano Petruzzelli, G. Cohuet, Ilaria Valente, Mario Scuri, Stefano Vezzoli, A Muraro
Publikováno v:
60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V..
Autor:
I Montagna, Helene Prunier, Dave Singh, Leonardo M. Fabbri, Jørgen Vestbo, Alberto Papi, Stefano Vezzoli, Mario Scuri, George Georges, Alessandro Guasconi, Stefano Petruzzelli, Massimo Corradi
Publikováno v:
Airway pharmacology and treatment.
Introduction: Exacerbations are an important outcome measure in COPD and recurrent events are of particular importance. Analysis of recurrent events provides an optimal evaluation of treatment effect. Aims and objectives: We report the results of a p
Autor:
Dave Singh, Ilaria Valente, Alberto Papi, George Georges, Alessandro Guasconi, Helene Prunier, Leonardo M. Fabbri
Publikováno v:
Airway pharmacology and treatment.
Autor:
Alberto Papi, Alessandro Guasconi, Helene Prunier, Leonardo M. Fabbri, Ilaria Valente, Dave Singh, George Georges
Publikováno v:
Airway pharmacology and treatment.
Rationale and objective: Treatment of COPD exacerbations with antibiotics and/or systemic corticosteroids maybe related to a different degree of event severity. TRIBUTE was a 52-week randomised controlled study showing a superior clinical effect with
Autor:
Mario Scuri, Jørgen Vestbo, Alberto Papi, Leonardo M. Fabbri, Helene Prunier, I Montagna, G. Cohuet, Dave Singh, Stefano Petruzzelli, Nicolas Roche, Massimo Corradi, Alessandro Guasconi, Stefano Vezzoli
Publikováno v:
Papi, A, Vestbo, J, Fabbri, L, Corradi, M, Prunier, H, Cohuet, G, Guasconi, A, Montagna, I, Vezzoli, S, Petruzzelli, S, Scuri, M, Roche, N & Singh, D 2018, ' Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial ', The Lancet, vol. 391, no. 10125, pp. 1076-1084 . https://doi.org/10.1016/S0140-6736(18)30206-X
Summary Background Evidence is scarce on the relative risk-benefit of inhaled triple therapy, consisting of inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting β 2 -agonist, versus dual bronchodilation for chronic obstructive